AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and Occupations
Thymus NeoplasmsThymus GlandThymus HyperplasiaPancreatic NeoplasmsNeoplasmsThymus PlantNeoplasms, Cystic, Mucinous, and SerousThymus ExtractsThymus HormonesSkin NeoplasmsThymectomyNeoplasms, Multiple PrimaryT-LymphocytesKidney NeoplasmsNeoplasms, Second PrimarySpleenThyroid NeoplasmsAdenocarcinoma, MucinousMyeloproliferative DisordersImmunohistochemistryDNA, NeoplasmLung NeoplasmsParotid NeoplasmsCystadenomaNeoplasms, ExperimentalNeoplasms, Connective and Soft TissueLiver NeoplasmsNeoplasms, Plasma CellAppendiceal NeoplasmsLymphomaCystadenoma, MucinousOvarian NeoplasmsEndocrine Gland NeoplasmsThymomaGastrointestinal NeoplasmsNeoplasms, Radiation-InducedCarcinoma, Pancreatic DuctalNeoplasms, Vascular TissueEye NeoplasmsNose NeoplasmsSalivary Gland NeoplasmsMice, Inbred C57BLAdenocarcinoma, PapillaryCarcinoma, PapillaryNeoplasm ProteinsLymphoid TissueTesticular NeoplasmsNeoplasms, Muscle TissueNeoplasms, Glandular and EpithelialThymocytesAntigens, NeoplasmAdenomaCystadenocarcinoma, MucinousSoft Tissue NeoplasmsHematologic NeoplasmsUterine NeoplasmsIntestinal NeoplasmsNeoplasms, Adnexal and Skin AppendageNeoplasm StagingVascular NeoplasmsCell DifferentiationSweat Gland NeoplasmsBone NeoplasmsPalatal NeoplasmsNeoplasms, Complex and MixedMandibular NeoplasmsCystadenocarcinomaMice, Inbred StrainsBile Duct NeoplasmsNeoplasm InvasivenessSplenic NeoplasmsDog DiseasesHeart NeoplasmsCystadenoma, SerousTumor Markers, BiologicalColonic NeoplasmsMaxillary NeoplasmsCattleT-Lymphocyte SubsetsAnal Gland NeoplasmsMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalBone Marrow NeoplasmsLymphocytesMice, TransgenicNeoplasms, Adipose TissueColorectal NeoplasmsMeningeal NeoplasmsLymph NodesDuodenal NeoplasmsMyasthenia GravisFlow CytometryAdrenal Cortex NeoplasmsMouth NeoplasmsReceptors, Antigen, T-CellTongue NeoplasmsMice, Inbred AKRAntigens, CD8Ileal NeoplasmsStomach NeoplasmsLiver Neoplasms, ExperimentalFetusImmunophenotypingUrinary Bladder NeoplasmsCarcinoma, Acinar CellCarcinomaSpinal Cord NeoplasmsVaginal NeoplasmsBone MarrowNeoplasm MetastasisAdenoma, OxyphilicNeoplasm Recurrence, LocalNervous System NeoplasmsAdenocarcinomaTomography, X-Ray ComputedMice, Inbred BALB CJanus Kinase 2Muscle NeoplasmsHemangiosarcomaDNAB-LymphocytesMyelodysplastic-Myeloproliferative DiseasesPancreatectomyLymphopoiesisPeripheral Nervous System NeoplasmsLipoma
Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Thymus Gland: A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.Thymus Hyperplasia: Enlargement of the thymus. A condition described in the late 1940's and 1950's as pathological thymic hypertrophy was status thymolymphaticus and was treated with radiotherapy. Unnecessary removal of the thymus was also practiced. It later became apparent that the thymus undergoes normal physiological hypertrophy, reaching a maximum at puberty and involuting thereafter. The concept of status thymolymphaticus has been abandoned. Thymus hyperplasia is present in two thirds of all patients with myasthenia gravis. (From Segen, Dictionary of Modern Medicine, 1992; Cecil Textbook of Medicine, 19th ed, p1486)Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Thymus Plant: A plant genus of the family LAMIACEAE best known for the thyme spice added to foods.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Thymus Extracts: Extracts of the thymus that contain specific, but uncharacterized factors or proteins with specific activities; three distinct substances are already known: thymotoxin, thymin and thymosin.Thymus Hormones: Humoral factors secreted by the thymus gland. They participate in the development of the lymphoid system and the maturation of the cellular immune response.Skin Neoplasms: Tumors or cancer of the SKIN.Thymectomy: Surgical removal of the thymus gland. (Dorland, 28th ed)Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Spleen: An encapsulated lymphatic organ through which venous blood filters.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.DNA, Neoplasm: DNA present in neoplastic tissue.Lung Neoplasms: Tumors or cancer of the LUNG.Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Liver Neoplasms: Tumors or cancer of the LIVER.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.Thymoma: A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Neoplasms, Radiation-Induced: Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Eye Neoplasms: Tumors or cancer of the EYE.Nose Neoplasms: Tumors or cancer of the NOSE.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Mice, Inbred C57BLAdenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Lymphoid Tissue: Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS.Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Neoplasms, Muscle Tissue: Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Thymocytes: HEMATOPOIETIC PROGENITOR CELLS that have migrated to the THYMUS where they differentiate into T-LYMPHOCYTES. Thymocytes are classified into maturational stages based on the expression of CELL SURFACE ANTIGENS.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Adenoma: A benign epithelial tumor with a glandular organization.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Uterine Neoplasms: Tumors or cancer of the UTERUS.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Neoplasms, Adnexal and Skin Appendage: Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Vascular Neoplasms: Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Sweat Gland NeoplasmsBone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Palatal Neoplasms: Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.Neoplasms, Complex and Mixed: Neoplasms composed of more than one type of neoplastic tissue.Mandibular Neoplasms: Tumors or cancer of the MANDIBLE.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Splenic Neoplasms: Tumors or cancer of the SPLEEN.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Heart Neoplasms: Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Colonic Neoplasms: Tumors or cancer of the COLON.Maxillary Neoplasms: Cancer or tumors of the MAXILLA or upper jaw.Cattle: Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.T-Lymphocyte Subsets: A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.Anal Gland Neoplasms: Tumors or cancer of the anal gland.Mediastinal Neoplasms: Tumors or cancer of the MEDIASTINUM.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Mice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Neoplasms, Adipose Tissue: Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Myasthenia Gravis: A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.Mouth Neoplasms: Tumors or cancer of the MOUTH.Receptors, Antigen, T-Cell: Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.Tongue Neoplasms: Tumors or cancer of the TONGUE.Mice, Inbred AKRAntigens, CD8: Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.Ileal Neoplasms: Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).Stomach Neoplasms: Tumors or cancer of the STOMACH.Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Fetus: The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN.Immunophenotyping: Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Carcinoma, Acinar Cell: A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Spinal Cord Neoplasms: Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.Vaginal Neoplasms: Tumors or cancer of the VAGINA.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Adenoma, Oxyphilic: A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Nervous System Neoplasms: Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Mice, Inbred BALB CJanus Kinase 2: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.Muscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)DNA: A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Myelodysplastic-Myeloproliferative Diseases: Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.Pancreatectomy: Surgical removal of the pancreas. (Dorland, 28th ed)Lymphopoiesis: Formation of LYMPHOCYTES and PLASMA CELLS from the lymphoid stem cells which develop from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW. These lymphoid stem cells differentiate into T-LYMPHOCYTES; B-LYMPHOCYTES; PLASMA CELLS; or NK-cells (KILLER CELLS, NATURAL) depending on the organ or tissues (LYMPHOID TISSUE) to which they migrate.Peripheral Nervous System Neoplasms: Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)Lipoma: A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.

Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. (1/1008)

Many types of tumor cells overexpress transforming growth factor beta (TGF-beta), which is believed to promote tumor progression. We hypothesized that overexpression of the extracellular region of the type II TGF-beta receptor (soluble TbetaRII) would compete for or block TGF-beta binding to TbetaRs on immune cells, preventing TGF-beta-mediated immunosuppression and consequently resulting in the eradication of tumor cells. We tested this in the mouse thymoma cell line EL4, which has been reported to suppress cellular immunity by secreting a large amount of TGF-beta. Transduction of EL4 with recombinant retrovirus encoding soluble TbetaRII resulted in the secretion of heterogeneously glycosylated, 25 to 35 kDa truncated TbetaRII. Inoculation of 1 x 10(4) to 5 x 10(4) soluble TbetaRII-modified EL4 cells (EL4/Ts, EL4 cells transduced with recombinant retrovirus encoding soluble TbetaRII and neomycin resistance gene) s.c. to mice showed reduced tumorigenicity, as indicated by lower overall tumor incidence (7%, 1 of 14; P < 0.001) compared with unmodified EL4 (100%, 9 of 9) or vector-modified EL4 cells (EL4/neo, EL4 cells transduced with recombinant retrovirus encoding neomycin resistance gene; 100%, 4 of 4). Administration of mitomycin C-treated EL4/Ts cells (1 x 10(6)) after EL4 inoculation (1 x 10(4)) reduced tumor incidence from 100% (5 of 5 in mice inoculated with mitomycin C-treated EL4/neo) to 40% (4 of 10, P < 0.05), indicating that supply of soluble TbetaRII could actually block TGF-beta-mediated tumorigenesis. In vitro tumor cytotoxicity assays revealed 3-5-fold higher cytotoxic activity with lymphocytes from EL4/Ts-bearing mice compared with those from EL4- or EL4/neo-bearing mice, indicating that the observed tumor rejection was mediated by restoration of the tumor-specific cellular immunity. These data suggest that expression of soluble TbetaRII is an effective strategy for treating highly progressive tumors secreting TGF-beta.  (+info)

Invasive thymoma with long-term survival by extensive reoperation. (2/1008)

The recurrence of invasive thymoma is often observed; however, no accepted treatment of recurrent invasive thymoma has yet been established. We herein report a 41-year-old woman with invasive thymoma and pleural dissemination who demonstrated long-term survival after undergoing 4 operations. Based on our findings, reoperation is thus suggested in patients with intrathoracic recurrence and long-term survival can be expected.  (+info)

Primary mediastinal malignancies: findings in 219 patients. (3/1008)

The purpose of this study was to determine the demographics, histology, methods of treatment, and survival in primary mediastinal malignancies. We did a retrospective review of the statewide New Mexico Tumor Registry for all malignant tumors treated between January 1, 1973 and December 31, 1995. Benign tumors and cysts of the mediastinum were excluded. Two hundred nineteen patients were identified from a total of 110,284 patients with primary malignancies: 55% of tumors were lymphomas, 16% malignant germ cell tumors, 14% malignant thymomas, 5% sarcomas, 3% malignant neurogenic tumors, and 7% other tumors. There were significant differences in gender between histologies (P < 0.001). Ninety-four percent of germ cell tumors occurred in males, 66% of neurogenic tumors were in females; other tumors occurred in males in 58% of cases. There were also significant differences in ages by histology (P < 0.001). Neurogenic tumors were most common in the first decade, lymphomas and germ cell tumors in the second to fourth decades, and lymphomas and thymomas in patients in their fifth decades and beyond. Stage at presentation (P = 0.001) and treatment (P < 0.001) also differed significantly between histologic groups. Five-year survival was 54% for lymphomas, 51% for malignant germ cell tumors, 49% for malignant thymomas, 33% for sarcomas, 56% for neurogenic tumors, and 51% overall. These survival rates were not statistically different (P > 0.50). Lymphomas, malignant germ cell tumors, and thymomas were the most frequently encountered malignant primary mediastinal neoplasms in this contemporary series of patients. Demographics, stage at presentation, and treatment modality varied significantly by histology. Despite these differences, overall five-year survival was not statistically different.  (+info)

Promoter element for transcription of unrearranged T-cell receptor beta-chain gene in pro-T cells. (4/1008)

The hallmark of T- and B-lymphocyte development is the rearrangement of variable (V), diversity (D), and joining (J) segments of T-cell receptor (TCR) and immunoglobulin (Ig) genes to generate a diverse repertoire of antigen receptor specificities in the immune system. The process of V(D)J recombination is shared in the rearrangement of all seven antigen receptor genes and is controlled by changes in chromatin structure, which regulate accessibility to the recombinase apparatus in a lineage- and stage-specific manner. These chromatin changes are linked to transcription of the locus in its unrearranged (germline) configuration. To understand how germline transcription of the TCRbeta-chain gene is regulated, we determined the structure of germline transcripts initiating near the Dbeta1 segment and identified a promoter within this region. The Dbeta1 promoter is active in the presence of the TCRbeta enhancer (Ebeta), and in this context, exhibits preferential activity in pro-T versus mature T-cell lines, as well as T- versus B-lineage specificity. These studies provide insight into the developmental regulation of TCRbeta germline transcription, one of the earliest steps in T-cell differentiation.  (+info)

Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. (5/1008)

Neuroendocrine tumors (NET) of the thyroid gland are rare. Apart from medullary thyroid carcinoma (MTC), metastases of gastroenteropancreatic (GEP) NET may also occur. Features of six patients (five men, one female: age range, 39-67 years) with thyroid metastases from a GEP-NET are described. Thyroid metastases were bilateral in all patients and were associated with enlarged neck lymph nodes in five. In four cases, the thyroid tumor was either the first sign of the disease (n = 2) or was an isolated site of recurrence (n = 2). The tumors were well (n = 3) or poorly differentiated (n = 3). Five tumors for which the primary site could be determined corresponded to foregut-derived tumors (3 lungs, 1 thymus and 1 pancreatic NET). One tumor demonstrated calcitonin (CT) production as shown by immunohistochemistry and elevated plasma CT levels. However, the disease history and the clinical features strongly favored a metastasizing GEP-NET. No tumoral RET proto-oncogene mutation was found in this patient. The differential diagnosis between metastatic GEP-NET and MTC is crucial because prognosis, work-up, and treatment differ greatly.  (+info)

Dermatomyositis associated with invasive thymoma. (6/1008)

We report a case of dermatomyositis (DM) associated with invasive thymoma in a 22-year-old woman who was admitted to our hospital complaining of dyspnea which required ventilation support. The reddened elevated scaly eruptions were prominent over the extensor surfaces. Chest X-ray and computed tomography showed mediastinal masses, which were diagnosed as mixed type thymoma. Muscle and skin biopsy specimens were compatible with DM. She was treated with methylprednisolone pulse therapy followed by extended removal of the anterior mediastinal tumor and subsequent radiotherapy. She has had a good clinical course without recurrence of thymoma or DM for more than 3 years. The role of thymoma in the development of DM is discussed.  (+info)

Novel endogenous type D retroviral particles expressed at high levels in a SCID mouse thymic lymphoma. (7/1008)

A xenograft model of the human disease Langerhans cell histiocytosis (LCH) was investigated with severe combined immunodeficiency (SCID) mice. Transplantation of human LCH biopsy material into SCID mice resulted in the generation of mouse tumors resembling lymphomas. A thymoma cell line (ThyE1M6) was generated from one of these mice and found to display significant levels of Mg2+-dependent reverse transcriptase activity. Electron microscopy revealed particles with type D retroviral morphology budding from ThyE1M6 cells at a high frequency, whereas control cultures were negative. Reverse transcription-PCR of virion RNA with degenerate primers for conserved regions of various mouse, human, and primate retroviruses amplified novel sequences related to primate type D retroviruses, murine intracisternal A particles, Jaagsiekte sheep retrovirus, and murine long interspersed nuclear elements but not other retroviral classes. We demonstrate that these sequences represent a novel group of endogenous retroviruses expressed at low levels in mice but expressed at high levels in the ThyE1M6 cell line. Furthermore, we propose that the activation of endogenous retroviral elements may be associated with a high incidence of thymomas in SCID mice.  (+info)

Sequences between the enhancer and promoter in the long terminal repeat affect murine leukemia virus pathogenicity and replication in the thymus. (8/1008)

We previously showed that the 93-bp region between the enhancer and promoter (named DEN for downstream of enhancer) of the long terminal repeat (LTR) of the MCF13 murine leukemia virus is an important determinant of the ability of this virus to induce thymic lymphoma. In this study we observed that DEN plays a role in the regulation of virus replication in the thymus during the preleukemic period. A NF-kappaB site in the DEN region partially contributes to the effect of DEN on both lymphomagenicity and virus replication. To further study the effects of DEN and the NF-kappaB site on viral pathogenicity during the preleukemic period, we examined replication of wild-type and mutant viruses with a deletion of the NF-kappaB site or the entire DEN region in the thymus. Thymic lymphocytes which were infected with wild-type and mutant viruses were predominantly the CD3(-) CD4(+) CD8(+) and CD3(+) CD4(+) CD8(+) cells. The increase in infection by wild-type virus and both mutant viruses of these two subpopulations during the preleukemic period ranged from 9- to 84-fold, depending upon the time point and virus. The major difference between the wild-type and both mutant viruses was the lower rate and lower level of mutant virus replication in these thymic subpopulations. Significant differences in replication between wild-type and both mutant viruses were seen in the CD3(-) CD4(+) CD8(+) and CD3(-) CD4(-) CD8(-) subpopulations, suggesting that these thymic cell types are important targets for viral transformation.  (+info)

The ITMIG/IASLC thymic epithelial tumors staging project: A proposed lymph node map for thymic epithelial tumors in the...The ITMIG/IASLC thymic epithelial tumors staging project: A proposed lymph node map for thymic epithelial tumors in the...
TY - JOUR. T1 - The ITMIG/IASLC thymic epithelial tumors staging project. T2 - A proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors. AU - Bhora, Faiz Y.. AU - Chen, David J.. AU - Detterbeck, Frank C.. AU - Asamura, Hisao. AU - Falkson, Conrad. AU - Filosso, Pier Luigi. AU - Giaccone, Giuseppe. AU - Huang, James. AU - Kim, Jhingook. AU - Kondo, Kazuya. AU - Lucchi, Marco. AU - Marino, Mirella. AU - Marom, Edith M.. AU - Nicholson, Andrew G.. AU - Okumura, Meinoshin. AU - Ruffini, Enrico. AU - Van Schil, Paul. AU - Goldstraw, Peter. AU - Rami-Porta, Ramón. AU - Ball, David. AU - Beer, David. AU - Beyruti, Ricardo. AU - Bolejack, Vanessa. AU - Chansky, Kari. AU - Crowley, John. AU - Eberhardt, Wilfried Ernst Erich. AU - Edwards, John. AU - Galateau-Sallé, Françoise. AU - Giroux, Dorothy. AU - Gleeson, Fergus. AU - Groome, Patti. AU - Kennedy, Catherine. AU - Kim, Young Tae. AU - Kingsbury, Laura. AU - Kondo, ...
Apoptosis in thymic epithelial tumors<...Apoptosis in thymic epithelial tumors<...
TY - JOUR. T1 - Apoptosis in thymic epithelial tumors. AU - Park, Sung Hye. AU - Kim, Han Kyeom. AU - Kim, Hanseong. AU - Ro, Jae Y.. PY - 2002/1/1. Y1 - 2002/1/1. N2 - We studied Fas/FasL, Bcl-2, and M30 CytoDeath in five cases of normal thymus and 41 cases of thymic epithelial tumors (TETs). In normal thymus, Fas was expressed in all epithelial cells, but not in thymic lymphocytes; FasL was weakly expressed only in medullary epithelium and Hassals corpuscles. In TETs, Fas was expressed in all epithelial cells and lymphocytes, while FasL was differently expressed in epithelial cells of different subtypes of TETs, i.e., type A (2/2), AB (12/12), B1 (0/9), B1/B2 (0/3), B2 (0/1), B2/B3 (1/3), B3 (6/10) and C (1/1), but not in lymphocytes. Bcl2 protein was strongly expressed in medullary-derived lymphocytes of normal thymus and TETs, and weakly expressed only in medullary (spindle) epithelium of TETs. On M30 CytoDeath immunostaining, apoptotic indices were very low in all TETs (0-1.2). In ...
Prognosis of surgically treated thymic epithelial tumors<...Prognosis of surgically treated thymic epithelial tumors<...
TY - JOUR. T1 - Prognosis of surgically treated thymic epithelial tumors. AU - Horinouchi, Hirohisa. AU - Asakura, Keisuke. AU - Kimura, Yoshishige. AU - Takeuchi, Ken. AU - Kawamura, Masafumi. AU - Watanabe, Masazumi. AU - Eguchi, Keisuke. AU - Kobayashi, Koichi. PY - 2006/11. Y1 - 2006/11. N2 - This study was performed to clarify the prognosis of patients with surgically treated thymic epithelial tumors. The records of 131 patients who underwent surgical treatment during 1985-2005 were retrospectively reviewed. Pathologic review was done according to the WHO classification of tumors of the thymus. Patients characteristics were: 76 male and 55 fimale; average age 53 (range 20-80) years; tumor stage was stage I in 42, stage II in 43, stage III in 23, stage IVa in 15, stage IVb in 1, and thymic carcinoma (squamous cell carcinoma) in 7 based on Masaokas staging. There were 7 cases of type A, 23 of type AB, 30 of type B1, 27 of type B2, 29 of type B3, and 15 of type C. Surgical procedures ...
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas |...Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas |...
To gain further insight into the biology of thymic tumors, we did a comprehensive molecular analysis of 45 resected thymic tumors. To our knowledge, this study represents one of the first and largest of its kind. Previous studies have focused on only a small number of tumors (29) and used only a limited number of analytic methods (29-31). Our analysis has three main new findings.. First, mutational analysis of genes encoding components of the EGFR signaling pathway led to the identification of RAS mutations in 3 (7%) of 45 thymic epithelial tumors. Previously, investigators have collectively assessed the status of only one RAS gene (i.e., KRAS) in 17 tumors (16, 32, 33) but did not identify any mutation. In our study, two RAS mutant tumors were thymomas (type A and B2) that are low grade, and the other tumor was a thymic carcinoma that is high grade. KRAS mutations predict for primary resistance to anti-EGFR directed therapies [i.e., gefitinib/erlotinib in lung cancer (34) and cetuximab in colon ...
Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on...Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on...
TY - JOUR. T1 - Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis. AU - Roden, Anja. AU - Yi, Eunhee S.. AU - Jenkins, Sarah M.. AU - Edwards, Kelly K.. AU - Donovan, Janis L.. AU - Lewis, Jean E.. AU - Cassivi, Stephen D.. AU - Marks, Randolph Stuart. AU - Garces, Yolanda Isabel. AU - Aubry, Marie Christine. PY - 2015/3/30. Y1 - 2015/3/30. N2 - Data regarding the prognostic significance of the histopathologic classifications of thymic epithelial neoplasms are contradictory, perhaps reflecting issues in reproducibility. We studied the effect of reproducibility of 3 histopathologic classifications on prognosis and investigated the interobserver agreement on invasion and its effect on staging and prognosis. A total of 456 patients who underwent surgery for thymic epithelial neoplasm at Mayo Clinic Rochester (1942 to 2008) were staged (modified Masaoka, proposed Moran, proposed IASLC/ITMIG) and independently classified ...
Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms...Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms...
TY - JOUR. T1 - Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 world health organization in patients treated with octreotide and prednisone. T2 - an eastern cooperative oncology group study. AU - Aisner, Seena C.. AU - Dahlberg, Suzanne. AU - Hameed, Meera R.. AU - Ettinger, David S.. AU - Schiller, Joan H.. AU - Johnson, David H.. AU - Aisner, Joseph. AU - Loehrer, Patrick J.. PY - 2010/6. Y1 - 2010/6. N2 - BACKGROUND:: Advanced or recurrent nonresectable thymic epithelial tumors show only a modest response to standard chemotherapy. A recent study using octreotide and prednisone in thymic tumors, Eastern Cooperative Oncology Group study E1C97, was conducted to verify the activity of octreotide for thymic tumors. The aim of this study was to determine whether epidermal growth factor receptor (EGFR) immunoreactivity correlated with outcomes and to identify new biologic markers for potential ...
YUHSpace: Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a...YUHSpace: Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a...
title: Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution., doi: 10.1016/j.ejcts.2009.02.019, category: Article
Search Results | JNCCNSearch Results | JNCCN
Overview Masses in the anterior mediastinum include neoplasms (e.g., thymomas, lymphomas, thymic carcinomas, thymic carcinoids, thymolipomas, germ cell tumors, parathyroid adenomas) or nonneoplastic conditions (e.g., intrathoracic goiter, thymic cysts, lymphangiomas, aortic aneurysms).1,2 Thymomas are the most common tumor in the anterior mediastinum.1,3,4 Many mediastinal masses are benign, especially those occurring in asymptomatic patients; however, symptomatic patients often have malignant mediastinal lesions. These guidelines outline the evaluation, treatment, and management of thymomas and thymic carcinomas (see Thymic Masses, opposite column). The WHO histologic classification system can be used to distinguish among thymomas, thymic carcinomas, and thymic carcinoids.3 Lymphomas typically manifest as generalized disease but can also be primary anterior mediastinal lesions (i.e., nodular sclerosing Hodgkin disease and non-Hodgkins lymphomas [large B-cell lymphoma and lymphoblastic ...
Search Results | JNCCNSearch Results | JNCCN
Overview Masses in the anterior mediastinum include neoplasms (e.g., thymomas, lymphomas, thymic carcinomas, thymic carcinoids, thymolipomas, germ cell tumors, parathyroid adenomas) or nonneoplastic conditions (e.g., intrathoracic goiter, thymic cysts, lymphangiomas, aortic aneurysms).1,2 Thymomas are the most common tumor in the anterior mediastinum.1,3,4 Many mediastinal masses are benign, especially those occurring in asymptomatic patients; however, symptomatic patients often have malignant mediastinal lesions. These guidelines outline the evaluation, treatment, and management of thymomas and thymic carcinomas (see Thymic Masses, opposite column). The WHO histologic classification system can be used to distinguish among thymomas, thymic carcinomas, and thymic carcinoids.3 Lymphomas typically manifest as generalized disease but can also be primary anterior mediastinal lesions (i.e., nodular sclerosing Hodgkin disease and non-Hodgkins lymphomas [large B-cell lymphoma and lymphoblastic ...
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. - Semantic ScholarCombining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. - Semantic Scholar
Recent work with immunotherapy has shown promising results with treatment of several solid malignancies, and there are several reports of good systemic responses with the combination of immunotherapy and radiation therapy (RT), most notably in advanced melanoma. Given the rapid increase in the use of checkpoint blockade as well as anti-tumor vaccines, we review here the preclinical rationale and ongoing clinical work in combining immunotherapy with RT for small cell lung cancer (SCLC) and thymic tumors. While there are several reports of promising results with the combination of immunotherapy and conventional systemic treatment, we focus here on the ongoing clinical studies that combine immunotherapy with RT, and highlight the emerging data for this multimodality approach as well as key preclinical and clinical issues that remain to be addressed. With regards to SCLC, trials exploring to the combination of immunotherapy and RT are already ongoing, but clinical studies for this combination in thymoma are
Molecular Markers for Patients with Thymic Malignancies: not Feasible at Present?Molecular Markers for Patients with Thymic Malignancies: not Feasible at Present?
Background: Thymomas and thymic carcinomas are rare malignancies and devising clinically effectivemolecular targeted therapies is a major clinical challenge. The aim of the study was to analyze BLC2 andvascular endothelial growth factor receptor (VEGFR) expression and KRAS and EGFR mutational status andto correlate them with the clinical characteristics of patients with thymomas and thymic carcinomas. Materialsand Methods: A total of 62 patients (mean age: 50.4±13.2 years) with thymomas and thymic carcinomas wereenrolled. The expression of BLC2 and VEGFR in tumor cells and normal tissues was evaluated by RT-PCR.The mutational status of the KRAS and EGFR genes was investigated by PCR with sequence specific primers.Results: The BLC2 and VEGFR expression levels did not differ significantly between tumor and normal tissues.Moreover, there were no clearly pathogenic mutations in KRAS or EGFR genes in any tumor. None of themolecular markers were significantly related to clinical outcomes. Conclusions:
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced Recurrent or Metastatic...Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced Recurrent or Metastatic...
Clinical trial for Recurrent Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Unresectable Thymic Carcinoma | Metastatic Thymic Carcinoma , Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced Recurrent or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
Plus itPlus it
A single mutation in the transcription factor GTF2I may help differentiate fast-growing cancers of the thymus that require aggressive treatment from slow-growing ones that dont require extensive therapy, according to a study published in Nature Genetics.. Conducted by researchers from Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, and the NCI, the study involved thymic epithelial tumors (TET), which are subdivided into thymomas and thymic carcinomas; thymomas are further classified into types A, AB, B1, B2, and B3 based on histological features. All begin in the epithelial cells of the thymus, a lymphatic system organ where T cells mature. Together, they account for only 0.2% to 1.5% of all cancers.. "In addition to being rare, there is an insufficient characterization of the genetic abnormalities in these tumors," says the studys senior investigator Guiseppe Giaccone, MD, PhD, associate director for clinical research at Georgetown. "Having a GTF2I mutation as a marker ...
350868 | Stanford Health Care350868 | Stanford Health Care
Thymic epithelial tumors (TET) are rare. Wingless and INT (WNT), NOTCH and sonic hedgehog pathway interactions between thymocytes and thymic stroma are important to thymus and T-cell development. We analyzed a thymoma tissue microarray (TMA) for glioma associated oncogene homolog 1 (GLI1), NOTCH1 and catenin (cadherin-associated protein, beta 1) (CTNNB1) expression as surrogate markers of sonic hedgehog, NOTCH and WNT pathway activity.GLI1, NOTCH1 and CTNNB1 expression were assayed in a tissue microarray of 68 TET and eight benign thymus by fluorescent immunohistochemistry (AQUA) as surrogates for activity of the sonic hedgehog, NOTCH and WNT pathways respectively.No difference in tumor GLI1 (mean 201 vs. 211, p=0.31), CTNNB1 (mean 222 vs. 306, p=0.66) or NOTCH1 expression (mean 317 vs. 325, p=0.82) was noted between thymic tumor and benign thymus.No evidence for preferential expression of GLI1, NOTCH1 or CTNNB1 was noted. High-throughput immunofluorescence using AQUA technology can help ...
Risk factors for thymus cancer - Canadian Cancer SocietyRisk factors for thymus cancer - Canadian Cancer Society
A risk factor is something (such as a behaviour, substance or condition) that increases the risk of developing cancer. There are no known risk factors for thymic tumours, but there are some possible risk factors. Most cancers are the result of many risk factors, but sometimes thymic tumours develop
Reading ToolsReading Tools
article{Mediastinum4558, author = {Kwon Joong Na and Samina Park and In Kyu Park and Young Tae Kim and Chang Hyun Kang}, title = {AB010. OA02.01: Comparison of factors affecting length of stay after surgery for thymic tumors: minimally invasive vs . open surgeries}, journal = {Mediastinum}, volume = {2}, number = {0}, year = {2018}, keywords = {}, abstract = {}, url = {http://med.amegroups.com/article/view/4558 ...
Insight Biotechnology limited : : THY761 : : Thymus disease spectrum (thymic cancer progression) tissue array, 76 cases/76 coresInsight Biotechnology limited : : THY761 : : Thymus disease spectrum (thymic cancer progression) tissue array, 76 cases/76 cores
Insight Biotechnology supply high quality reagents for cell and molecular biology, specializing in antibodies for medical research.
Thymic carcinoma | Thymus | Tumor tissue | Acovos | Human FFPE tissueThymic carcinoma | Thymus | Tumor tissue | Acovos | Human FFPE tissue
Need for customized tissue samples?. If you need a more differentiated selection of samples, cannot find what you are looking for, or wish a consultation, please do not hesitate using our contact form or get in touch via phone or email. » [email protected] ...
Mediastinum - Squamous cell thymic carcinoma, nonkeratinizingMediastinum - Squamous cell thymic carcinoma, nonkeratinizing
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patients clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...
KAKEN - Researchers | MASAOKA Naoki (50199668)KAKEN - Researchers | MASAOKA Naoki (50199668)
Affiliation：東京女子医科大学,医学部,教授, Research Field：Obstetrics and gynecology,Hygiene, Keywords：フリーラジカル,胎児脳神経障害,アロプリノール,NMDAレセプター,臍帯,モンテビオ単位,子宮筋弛緩剤,胎児(仔)呼吸様運動,パワー値,umbilical cord, # of Research Projects：5, # of Research Products：8
Thymic epithelial tumours in Iceland: incidence and histopathology, a population-based study.Thymic epithelial tumours in Iceland: incidence and histopathology, a population-based study.
The objective of this study was to re-examine histologically and restage thymic epithelial tumours during a 25-year period and to correlate clinical and follow-up data. We utilized centralized registries in Iceland to establish a true nationwide incidence rate, previously unreported. A retrospective whole population study was carried out by including all patients diagnosed with a thymic epithelial tumour in Iceland between 1 January 1984 and 30 April 2010. Medical records were reviewed and presenting symptoms, diagnostic procedures and surgical outcome tabulated. The histology of all cases was reclassified according to the 2004 World Health Organization classification (A-TC). The Masaoka system was used for tumour staging. Median follow-up was 67 months. A total of 19 patients were identified, 11 men (58%) and 8 women, with mean age at presentation of 63 years (31-87 years). The age-standardized incidence rate (ASR) was 0.3 and 0.2/100 000/year for men and women, respectively. Types B2 (n = 5) ...
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma<...Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma<...
TY - JOUR. T1 - Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. AU - Lemma, Girum L.. AU - Lee, Ju Whei. AU - Aisner, Seena C.. AU - Langer, Corey J.. AU - Tester, William J.. AU - Johnson, David H.. AU - Loehrer, Patrick J.. PY - 2011/5/20. Y1 - 2011/5/20. N2 - Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response ...
Expression and polymorphisms of T cell immunoglobulin domain and mucin domain protein-1 in thymoma with or without myasthenia...Expression and polymorphisms of T cell immunoglobulin domain and mucin domain protein-1 in thymoma with or without myasthenia...
The present study aimed to investigate the expression and association of the single-nucleotide polymorphism (SNP) -1637A/G in the promoter region of the T cell immunoglobulin domain and mucin domain protein-1 (Tim-1) gene in patients diagnosed with thymoma with or without myasthenia gravis (MG). The expression of Tim-1 was detected using the streptavidin peroxidase immunohistochemical staining method on tissues obtained from thymoma patients with (n=58) and without (n=62) MG. The Tim-1 gene -1637A/G polymorphism was detected using the single allele-specific primer polymerase chain reaction. The positive rate of Tim-1 expression in thymoma patients with MG was 62.1% (32/58), which was significantly higher compared with that in thymoma patients without MG (33.9%, 21/62) (P=0.002). The genotype frequencies of GG, GA and AA in the -1637A/G polymorphism were 0.7931, 0.2069 and 0, respectively, in thymoma patients with MG, and 0.6129, 0.3871 and 0, respectively, in thymoma patients without MG. A ...
Mediastinal Thymolipoma with Striated Myoid Cells: Report of a Peculiar Case - Semantic ScholarMediastinal Thymolipoma with Striated Myoid Cells: Report of a Peculiar Case - Semantic Scholar
pISSN 1738-1843 eISSN 2092-8920 © 2013 The Korean Society of Pathologists/The Korean Society for Cytopathology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Thymolipoma is a rare anterior mediastinal tumor composed of mature adipose tissue and benign thymic tissue, and is a benign neoplasm for which complete surgical excision is curative. Literature has reported that the thymic parenchyma of thymolipoma exceptionally contain myoid cells that are immunoreactive for desmin, muscle-specific actin and myoglobin. Herein, we describe a very rare case of thymolipoma with myoid cells. To the best of our knowledge, this is the sixth case of thymolipoma containing striated myoid cells in the English literature since 1972.
Advantages of additional PET vs. MRI in the clinical diagnosis of anterior mediastinal tumorsAdvantages of additional PET vs. MRI in the clinical diagnosis of anterior mediastinal tumors
The present study retrospectively examined the diagnostic utility of adding positron emission tomography (PET) or magnetic resonance imaging (MRI) to computed tomography (CT) alone for preoperative diagnosis of anterior mediastinal tumors. A total of 104 consecutive patients who had undergone surgical resection of anterior mediastinal tumors were divided into two groups: Additional PET to another modality and no additional PET to another modality, and further subdivided into three groups: CT alone, additional MRI to CT and additional PET to CT. The sensitivity, specificity, and accuracy for diagnosing malignant tumors in each subgroup was calculated. Comparing the two groups, the diagnostic sensitivity was similar for additional PET (98.0%) and no additional PET (95.2%) groups; however, the specificity and accuracy for additional PET (75.0 and 92.2%, respectively) were significantly improved compared with no additional PET (31.6 and 65.0%, respectively). In the subgroup analysis, adding PET to ...
Thymoma and Thymic Carcinoma Treatment Cost in India | Thymoma and Thymic Carcinoma Treatment in India | Vaidam.comThymoma and Thymic Carcinoma Treatment Cost in India | Thymoma and Thymic Carcinoma Treatment in India | Vaidam.com
Thymoma and Thymic Carcinoma Treatment cost in India starts from USD . Find affordable packages, best specialists, hospitals and patient experiences for Thymoma and Thymic Carcinoma Treatment in India through Vaidam.
Childhood Thymoma and Thymic Carcinoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - WellSpan Health...Childhood Thymoma and Thymic Carcinoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - WellSpan Health...
Thymoma and thymic carcinoma originate within the epithelial cells of the thymus, resulting in an anterior mediastinal mass. The term thymoma is customarily used to describe neoplasms that show no overt atypia of the epithelial component, whereas, a thymic epithelial tumor that exhibits clear-cut cytologic atypia and...
Multimodality Treatment for Thymic Carcinoma: Review of 11 Cases at a Single InstituteMultimodality Treatment for Thymic Carcinoma: Review of 11 Cases at a Single Institute
ABSTRACT. Background: We reported our experience with thymic carcinomas and review their clinical features, treatment strategies, and prognoses. Methods: From April 1998 to November 2012, 11 patients pathologically diagnosed with thymic carcinoma and treated in our hospital were investigated. Results: There were 7 men and 4 women, with a median age of 62 years (range, 35 - 72). According to the Masaoka staging system, 3 patients had stage II, 1 stage III disease, 3 stage IVa disease and 4 stage IVb disease. Ten patients had squamous cell carcinoma, whereas 1 had large cell neuroendocrine carcinoma (LCNEC). We performed surgery or multimodality therapy including surgery as the initial therapy for 8 patients. Of the non-surgical cases, 1 patient received chemoradiotherapy and survived for over 6 years without recurrence, whereas 2 received palliative care. Three of 4 patients who underwent complete resection survived without disease recurrence, whereas only 1 patient with LCNEC survived in the ...
Thymoma and Thymic Carcinoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] | HealthLink BCThymoma and Thymic Carcinoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] | HealthLink BC
Disease Overview Thymomas and thymic carcinomas are epithelial tumors of the thymus. The term, thymoma, is customarily used to describe neoplasms that show no overt atypia of the epithelial component. A thymic epithelial tumor that exhibits clear-cut cytologic atypia and histologic features no longer specific to the...
Primary Mediastinal Neoplasms | Radiology KeyPrimary Mediastinal Neoplasms | Radiology Key
In 1999, the World Health Organization (WHO) Consensus Committee published a histologic classification of tumors of the thymus. In this scheme, thymomas are classified on the combined basis of the morphology of the neoplastic epithelial cells and the lymphocyte-to-epithelial cell ratio. This classification has resulted in six separate histologic subtypes of thymomas (types A, AB, B1, B2, B3, and C) (Table 7-1). An update on the WHO classification was published in 2004.27 It retained its classifications of A through B3 thymomas but relegated type C to a separate category of thymic carcinoma and acknowledged that certain types of thymoma do not fall into these categories. The applicability and clinical significance of the WHO histologic classification of thymomas is still being evaluated. It appears that most thymomas can be classified using the WHO criteria, although the clinical and prognostic relevance of this classification has not been conclusively determined. Most thymomas of types A and AB ...
FULL TEXT - Incidentally detected superior mediastinal thymoma: An interesting case report - Journal of Case Reports and Images...FULL TEXT - Incidentally detected superior mediastinal thymoma: An interesting case report - Journal of Case Reports and Images...
Introduction: Thymic malignancies represent a wide range of clinical, histological and molecular entities, with considerable heterogeneity even among tumors of the same histotype. Thymomas are rare neoplasms arising from tissue elements of the thymus and developing in the anterior mediastinum, with an annual incidence of only 0.15 cases per 100, 000 person-years. They can be associated with a variety of systemic and autoimmune disorders, such as pure red cell aplasia, pancytopenia, hypogammaglobulinemia, collagen-vascular disease, and most commonly with myasthenia gravis. Surgical resection remains the cornerstone of therapy for early-stage disease, while in advanced or recurrent forms, a multimodality approach incorporating radiation and chemotherapy is required. Platinum with anthracycline-based chemotherapy is an optimal combination for advanced thymoma. Case Report: We hereby present an interesting case of thymoma which was detected on imaging for routine health check-up and was managed successfully
A clinicopathologic study of mediastinal lesions with special emphasis on thymomas - MAHE Digital RepositoryA clinicopathologic study of mediastinal lesions with special emphasis on thymomas - MAHE Digital Repository
Background: Mediastinal masses are relatively uncommon lesions that sometimes pose an interesting diagnostic and therapeutic problem for the clinician. Thymomas are one of the common mediastinal neoplasms and exhibit a wide spectrum of morphologic features and an unrivalled frequency of other autoimmune diseases. The great morphologic variability and heterogeneity in thymomas has rendered their histological classification difficult and highly controversial. Methods: This retrospective and descriptive study on thymoma was done in the department of pathology, Kasturba Medical College Mangalore (Manipal University), India over a period of five years from January 2006 to June 2011. Histopathology sections taken were stained with routine Hematoxylin and Eosin stains in every case. Additional stains and immunohistochemistry were done as required. Results: Total number of mediastinal lesions studied was 66, with thymomas making up 15 cases. The age range of patients with thymomas was 22 to 65 years ...
Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted TherapiesHypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM).|i| Case Description|/i|. We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy. Subsequently, refractory hypercalcemia persisted despite the administration of bisphosphonates and denosumab indicative of refractory hypercalcemia. Elevated 1,25-dihydroxyvitamin D was noted from the second admission with hypercalcemia responding to glucocorticoid administration. A subsequent PTHrP was also elevated, further supporting multiple mechanistic evolution of HCM. The different mechanisms of HCM are summarized with the role of tailoring therapies based on the particular
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of ChemotherapyStudy Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma pre
Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms...Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms...
Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 world health organization in patients treated with octreotide and prednisone: an eastern cooperative oncology group study Academic Article ...
Thymoma and Thymic Carcinoma Treatment (PDQ®): Treatment - Patient Information [NCI] | PeaceHealthThymoma and Thymic Carcinoma Treatment (PDQ®): Treatment - Patient Information [NCI] | PeaceHealth
Thymoma and thymic carcinoma are diseases in which malignant (cancer) cells form on the outside surface of the thymus. The thymus, a small organ that lies in the upper chest under the breastbone, is part of the lymph system. It makes white blood cells, called lymphocytes, that protect the body against infections...
What Are Thymoma and Thymic Carcinoma?What Are Thymoma and Thymic Carcinoma?
Learn about thymoma and thymic carcinoma, two cancers affecting the thymus. Its a small gland that makes white blood cells that fight infection.
IUCRO-0031; Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma |...IUCRO-0031; Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma |...
IUCRO-0031; Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma study is currently recruiting healthy volunteers at Indiana CTSI, IN
thymoma - Humpath.com - Human pathologythymoma - Humpath.com - Human pathology
thymomas WP WebPathology PO Definition: Thymoma is the most frequent tumor arising in human thymus (thymic tumors). Thymoma is a tumor (...)
Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B lymphopenia | Blood | American...Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B lymphopenia | Blood | American...
The main characteristics of the patients included in this study are shown in Table 1. Tumor histology has been classified according to the World Health Organization (WHO) proposal.16 The majority of the patients received thymectomy and showed an inversion of the CD4+/CD8+ ratio. Five patients were suffering from severe immunodeficiency syndrome characterized by recurrent infections of the lower respiratory tract. Flow cytometry analyses were performed at monthly intervals in the last 6 months, showing a stable reduction of mature CD19+ peripheral cells (unique patient numbers [UPNs] 091, 157, 051, 009, 147). A marked hypogammaglobulinemia had been detected in 4 of the 5 patients, whereas 1 of them (UPN 091) had normal immunoglobulin (Ig) serum levels. On the bases of clinical signs and B lymphopenia, we classified these patients as suffering from Good syndrome. We included in the study also 2 thymoma patients with normal Ig serum levels, normal B-cell counts, and no signs of severe recurrent ...
Thymoma - Symptoms, Diagnosis, Staging, Treatment & PrognosisThymoma - Symptoms, Diagnosis, Staging, Treatment & Prognosis
Thymomas are usually benign tumors, but they can also be malignant. Thymomas are rare tumors often associated with an autoimmune disease, the most common of which is myasthenia gravis.
Zarina AL | Medicine & HealthZarina AL | Medicine & Health
Thymomas comprise about 1% of all mediastinal tumours and are rare in children. Typically, these tumours are aggressive, with a poor outcome. The current treatment of invasive thymoma is often multidisciplinary. We report a 16-year-old boy with invasive thymoma who was successfully treated with systemic chemotherapy, surgical resection and irradiation. The patient has been in continuous remission for 6 years without radiographic evidence of tumour recurrence.. ...
Best Thymomas Doctor in Mumbai, Thymomas Doctors | CredihealthBest Thymomas Doctor in Mumbai, Thymomas Doctors | Credihealth
Find the best thymomas doctors in Mumbai. Get guidance from medical experts to select thymomas specialist in Mumbai from trusted hospitals - credihealth.com
Factors influencing the length of stay after mediastinal tumor resection in the setting of an enhanced recovery after surgery ...Factors influencing the length of stay after mediastinal tumor resection in the setting of an enhanced recovery after surgery ...
Factors influencing the length of stay after mediastinal tumor resection in the setting of an enhanced recovery after surgery (ERAS)-TUBELESS protocol
Mediastinal Tumors - Brigham and Womens HospitalMediastinal Tumors - Brigham and Women's Hospital
Learn about mediastinal tumors and how our team can best help you by using novel approaches to biopsies and minimally invasive, video-assisted procedures.
Mediastinal Tumors | RWJBarnabas HealthMediastinal Tumors | RWJBarnabas Health
Mediastinal Tumors - RWJBarnabas Health is a leading provider of compassionate, quality, & cost-efficient medical care services in the state of New Jersey.
Article: Goods syndrome: an uncommon cause of therapy-resistant diarrhoea (abstract) - August 2016 - NJMArticle: Good's syndrome: an uncommon cause of therapy-resistant diarrhoea (abstract) - August 2016 - NJM
Diarrhoea is a common symptom for which the aetiology will be straightforward in many cases. However, when a common aetiology is not found, the wide variety of other options can feel like finding a needle in a haystack. In this case report, we describe a patient who was referred to our centre with therapy-resistant, secretory diarrhoea, which was the presenting symptom of Goods syndrome, a rare form of adult-onset immunodeficiency associated with thymoma. The conclusions from this case report give direction for finding the needle and contribute to a focused approach to patients who present with therapyresistant diarrhoea ...
Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer - Full Text View - ClinicalTrials.govNeoadjuvant Chemotherapy for Locally Advanced Thymic Cancer - Full Text View - ClinicalTrials.gov
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic...Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Malignant epithelioid tumor (probably Thymoma B3 type), need IHC | Talk BioMalignant epithelioid tumor (probably Thymoma B3 type), need IHC | Talk Bio
Patient ID: 703/19, Format: FFPE, Type: Tumor, Sample Vol mL: , Gender: Male, Age: 32, Race: Caucasian, Ethnicity: Slavic, Organ: Mediastinum, Clinical Diagnosis: Mediastinal carcinoma, Pathological Diagnosis: Malignant epithelioid tumor (probably Thymoma B3 type), need IHC, T, N, M = T3, Nx, Mx, Grade: G1, Stage: III, Lymph Node Metastases: no, Distant Metastasis: no, Tumour = 80%, Necrosis = 0%, Hours & Minutes before fixation in formalin = 015, HIV = Neg, HEP B = Neg, HEP C = Neg, Patients Height: cm, Patients Weight: kg, Current Medications: , Smoking: , Smoking Type: , Smoking Pack/Day = , Smoking Duration Years = , Smoking When Quit: , Alcohol: , Drug Use: , Hormonal Therapy: no, Prev Chemotherapy: no, Prev Radiation: no, Current Procedure/Operation: resection, Date of Procurement: 43556, Country of Collection: Georgia
Light micrograph of a normal thymus - Stock Image P264/0004 - Science Photo LibraryLight micrograph of a normal thymus - Stock Image P264/0004 - Science Photo Library
Light micrograph of normal human thymus. The thymus is divided into lobules separated by septa of connective tissue (white spaces) which may contain blood vessels (as at right, stained red and very dark purple). Each lobule has a cortex (granular masses, densley packed, picture periphery) of lymphocytes, and a medulla (centre) of lymphocytes and stellate epitherial cells. The circular pink structures within the medulla (one prominent) are concentrically arranged epitherial cells of uncertain function. Magnificaton: x20 at 35mm size. - Stock Image P264/0004
Mediastinal tumorMediastinal tumor
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited ...
Mediastinal TumorsMediastinal Tumors
Infectious Disease Advisor is used by specialists and other medical professionals to help understand and treat infectious diseases. Latest news, research and treatment articles.
Pediatric Thymoma: Background, Pathophysiology, EpidemiologyPediatric Thymoma: Background, Pathophysiology, Epidemiology
Thymoma is a neoplasm of thymic epithelial cells. This definition excludes other tumors that may affect the thymus, such as lymphoma and germ cell tumors.
what part of the body does a thymoma affect? | Answers from Doctors | HealthTapwhat part of the body does a thymoma affect? | Answers from Doctors | HealthTap
Dr. Michael Thompson answered: Thymus: A thymoma is a tumor of the thymus, a gland in the anterior chest. This gland is present as ...
Diagnosis of thymoma: Costs for treatment #273927 in Germany | BookingHealthDiagnosis of thymoma: Costs for treatment #273927 in Germany | BookingHealth
Diagnosis of thymoma (costs for program #273927) ✔ University Hospital Ulm ✔ Department of General and Abdominal Surgery ✔ BookingHealth.com
Reading ToolsReading Tools
article{{Mediastinum}{4556}, author = {Casini, B., Sarti, D., Gallo, E., Alessandrini, G., Cecere, F., Pescarmona, E., Facciolo, F., Marino, M.}, title = {AB008. OA01.08: Thymic carcinoma: preliminary data of next generation sequencing analysis}, journal = {Mediastinum}, volume = {2}, number = {0}, year = {2018}, url = {http://med.amegroups.com/article/view/4556 ...
Compositions and Methods for the Identification, Assessment, Prevention and Therapy of Thymic Lymphoma or Hamartomatous...Compositions and Methods for the Identification, Assessment, Prevention and Therapy of Thymic Lymphoma or Hamartomatous...
Csh1 245 -3.31E+00 Melk 246 -3.30E+00 1459742_at 247 -3.30E+00 Nmnat3 248 -3.30E+00 A930015G24Rik 249 -3.29E+00 2810417H13Rik 250 -3.29E+00 Mrgprb1 251 -3.29E+00 1700061G19Rik 252 -3.29E+00 1459554_at 253 -3.28E+00 14378G7_at 254 -3.27E+00 Ceacam13 255 -3.27E+00 A130019P10Rik 256 -3.27E+00 Aqp11 257 -3.27E+00 2310047C04Rik 258 -3.27E+00 Dpp4 259 -3.27E+00 Otud1 260 -3.27E+00 1442468_at 261 -3.26E+00 B230101F01Rik 262 -3.26E+00 Tal2 263 -3.26E+00 Cplx1 264 -3.26E+00 Slc25a27 265 -3.26E+00 Spsb4 266 -3.25E+00 Mtm1 267 -3.25E+00 Bambi-ps1 268 -3.25E+00 1432510_ai 269 -3.25E+00 Pcmtd2 270 -3.25E+00 Clec2h 271 -3.24E+00 4930535E21Rik 272 -3.24E+00 1457234_at 273 -3.24E+00 Gm172 274 -3.23E+00 Gm996 275 -3.22E+00 E130014H08Rik 276 -3.22E+00 H2afy2 277 -3.22E+00 Defb3 278 -3.21E+00 Rbbp8 279 -3.20E+00 Dnase1l2 280 -3.19E+00 Sesn1 281 -3.19E+00 Accn3 282 -3.18E+00 4921537P18Rik 283 -3.18E+00 Hsd17b13 284 -3.18E+00 1810044A24Rik 285 -3.18E+00 Gas5 286 -3.18E+00 Flcn 287 -3.17E+00 Igh-4///Igh-6///Igh-V 288 ...
MEN1MEN1
Thymoma-associated multiorgan autoimmunityThymoma-associated multiorgan autoimmunity
CarcinomaCarcinoma
C37C37
CD5 (protein)CD5 (protein)
List of diseases (T)List of diseases (T)
ThymusThymus
CarcinomaCarcinoma
ICD-10 Chapter II: NeoplasmsICD-10 Chapter II: Neoplasms
Acinic cell carcinoma of the lungAcinic cell carcinoma of the lung
List of ICD-9 codes 140-239: neoplasmsList of ICD-9 codes 140-239: neoplasms
LymphomaLymphoma
Myeloid tissueMyeloid tissue
Conjunctival squamous cell carcinomaConjunctival squamous cell carcinoma
Squamous cell carcinomaSquamous cell carcinoma
Laboratory ratLaboratory rat
Laboratory ratLaboratory rat
Philip E. BernatzPhilip E. Bernatz
Neuroendocrine tumorNeuroendocrine tumor
Large cell neuroendocrine carcinoma of the lungLarge cell neuroendocrine carcinoma of the lung
CD3 (immunology)CD3 (immunology)
Mediastinal tumorMediastinal tumor
Canine histiocytic diseasesCanine histiocytic diseases
Adenosquamous lung carcinomaAdenosquamous lung carcinoma
Acinar adenocarcinomaAcinar adenocarcinoma
Salivary gland-like carcinoma of the lungSalivary gland-like carcinoma of the lung
CD44CD44
Henry Harrington JanewayHenry Harrington Janeway
TMEM229BTMEM229B
PAX8PAX8
PAX8PAX8
Index of HIV/AIDS-related articlesIndex of HIV/AIDS-related articles
CarcinoidCarcinoid
Non-small-cell lung carcinomaNon-small-cell lung carcinoma
Targeted therapy of lung cancerTargeted therapy of lung cancer
Category:Infobox medical condition (new)Category:Infobox medical condition (new)
ಆಕ್ಸಿಟೋಸಿನ್‌ - ವಿಕಿಪೀಡಿಯಆಕ್ಸಿಟೋಸಿನ್‌ - ವಿಕಿಪೀಡಿಯ
Tüümus - VikipeediaTüümus - Vikipeedia
Chest radiographChest radiograph
PathologyPathology
Multiple endocrine neoplasiaMultiple endocrine neoplasia
Lymphoid leukemiaLymphoid leukemia
Giant-cell carcinoma of the lungGiant-cell carcinoma of the lung
Stem cell markerStem cell marker
List of MeSH codes (C04)List of MeSH codes (C04)
LY75LY75
Lloyd J. OldLloyd J. Old
FOXN1FOXN1
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and Occupations
Thymus NeoplasmsThymus GlandThymus HyperplasiaPancreatic NeoplasmsNeoplasmsThymus PlantNeoplasms, Cystic, Mucinous, and SerousThymus ExtractsThymus HormonesSkin NeoplasmsThymectomyNeoplasms, Multiple PrimaryT-LymphocytesKidney NeoplasmsNeoplasms, Second PrimarySpleenThyroid NeoplasmsAdenocarcinoma, MucinousMyeloproliferative DisordersImmunohistochemistryDNA, NeoplasmLung NeoplasmsParotid NeoplasmsCystadenomaNeoplasms, ExperimentalNeoplasms, Connective and Soft TissueLiver NeoplasmsNeoplasms, Plasma CellAppendiceal NeoplasmsLymphomaCystadenoma, MucinousOvarian NeoplasmsEndocrine Gland NeoplasmsThymomaGastrointestinal NeoplasmsNeoplasms, Radiation-InducedCarcinoma, Pancreatic DuctalNeoplasms, Vascular TissueEye NeoplasmsNose NeoplasmsSalivary Gland NeoplasmsMice, Inbred C57BLAdenocarcinoma, PapillaryCarcinoma, PapillaryNeoplasm ProteinsLymphoid TissueTesticular NeoplasmsNeoplasms, Muscle TissueNeoplasms, Glandular and EpithelialThymocytesAntigens, NeoplasmAdenomaCystadenocarcinoma, MucinousSoft Tissue NeoplasmsHematologic NeoplasmsUterine NeoplasmsIntestinal NeoplasmsNeoplasms, Adnexal and Skin AppendageNeoplasm StagingVascular NeoplasmsCell DifferentiationSweat Gland NeoplasmsBone NeoplasmsPalatal NeoplasmsNeoplasms, Complex and MixedMandibular NeoplasmsCystadenocarcinomaMice, Inbred StrainsBile Duct NeoplasmsNeoplasm InvasivenessSplenic NeoplasmsDog DiseasesHeart NeoplasmsCystadenoma, SerousTumor Markers, BiologicalColonic NeoplasmsMaxillary NeoplasmsCattleT-Lymphocyte SubsetsAnal Gland NeoplasmsMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalBone Marrow NeoplasmsLymphocytesMice, TransgenicNeoplasms, Adipose TissueColorectal NeoplasmsMeningeal NeoplasmsLymph NodesDuodenal NeoplasmsMyasthenia GravisFlow CytometryAdrenal Cortex NeoplasmsMouth NeoplasmsReceptors, Antigen, T-CellTongue NeoplasmsMice, Inbred AKRAntigens, CD8Ileal NeoplasmsStomach NeoplasmsLiver Neoplasms, ExperimentalFetusImmunophenotypingUrinary Bladder NeoplasmsCarcinoma, Acinar CellCarcinomaSpinal Cord NeoplasmsVaginal NeoplasmsBone MarrowNeoplasm MetastasisAdenoma, OxyphilicNeoplasm Recurrence, LocalNervous System NeoplasmsAdenocarcinomaTomography, X-Ray ComputedMice, Inbred BALB CJanus Kinase 2Muscle NeoplasmsHemangiosarcomaDNAB-LymphocytesMyelodysplastic-Myeloproliferative DiseasesPancreatectomyLymphopoiesisPeripheral Nervous System NeoplasmsLipoma
Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on...Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on...
Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms...Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms...
YUHSpace: Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a...YUHSpace: Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a...
Prognosis of surgically treated thymic epithelial tumors<...Prognosis of surgically treated thymic epithelial tumors<...
Spindle Epithelial Tumour with Thymus-like Differentiation (Settle): A Distinctive Malignant Thyroid Neoplasm: A Case Report |...Spindle Epithelial Tumour with Thymus-like Differentiation (Settle): A Distinctive Malignant Thyroid Neoplasm: A Case Report |...
ICD-10-CM Code C37 - Malignant neoplasm of thymusICD-10-CM Code C37 - Malignant neoplasm of thymus
Thymus Cancer | Thymoma | MedlinePlusThymus Cancer | Thymoma | MedlinePlus
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage - Full Text View - ClinicalTrials.govBelinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage - Full Text View - ClinicalTrials.gov
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment - Full Text View - ClinicalTrials.govSunitinib for Advanced Thymus Cancer Following Earlier Treatment - Full Text View - ClinicalTrials.gov
Thymus - WikipediaThymus - Wikipedia
2020 ICD-10-CM Code Z85.23: Personal history of malignant neoplasm of thymus2020 ICD-10-CM Code Z85.23: Personal history of malignant neoplasm of thymus
Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized...Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized...
Lymph Nodes, Spleen & ThymusLymph Nodes, Spleen & Thymus
Yellow Fever VaccineYellow Fever Vaccine
Draft ICD-10-CM/PCS MS-DRGv28 Definitions ManualDraft ICD-10-CM/PCS MS-DRGv28 Definitions Manual
Recent thymic emigrants and prognosis in T- and B-cell childhood hematopoietic malignanciesRecent thymic emigrants and prognosis in T- and B-cell childhood hematopoietic malignancies
JMIR - From Information Seekers to Innovators: Qualitative Analysis Describing Experiences of the Second Generation of E...JMIR - From Information Seekers to Innovators: Qualitative Analysis Describing Experiences of the Second Generation of E...
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic...Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic...
2020 ICD-10-CM Diagnosis Code E32.9: Disease of thymus, unspecified2020 ICD-10-CM Diagnosis Code E32.9: Disease of thymus, unspecified
Yellow Fever Symptoms, Vaccine, Treatment & HistoryYellow Fever Symptoms, Vaccine, Treatment & History
P17 - Neoplasms by Individual Animal (systemic lesions abridged) (Rats)P17 - Neoplasms by Individual Animal (systemic lesions abridged) (Rats)
Clinical Features of Thymus Pathology | Springer for Research & DevelopmentClinical Features of Thymus Pathology | Springer for Research & Development
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugatesIn vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates
GTF2I Gene - GeneCards | GTF2I Protein | GTF2I AntibodyGTF2I Gene - GeneCards | GTF2I Protein | GTF2I Antibody
TMSB4X Gene - GeneCards | TYB4 Protein | TYB4 AntibodyTMSB4X Gene - GeneCards | TYB4 Protein | TYB4 Antibody
HLA-DQB1 | Cancer Genetics WebHLA-DQB1 | Cancer Genetics Web
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine...Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine...
Similar articles for PubMed (Select 22653258) - PubMed - NCBISimilar articles for PubMed (Select 22653258) - PubMed - NCBI
Yellow Fever - Chapter 4 - 2020 Yellow Book | Travelers Health | CDCYellow Fever - Chapter 4 - 2020 Yellow Book | Travelers' Health | CDC
2019 ICD-10-CM Diagnosis Code C75: Malignant neoplasm of other endocrine glands and related structures2019 ICD-10-CM Diagnosis Code C75: Malignant neoplasm of other endocrine glands and related structures
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic CancerA Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
025532 - 129S.Cg-Crebbp|tm1Jvd|/J025532 - 129S.Cg-Crebbp|tm1Jvd|/J
Neuroendocrine Tumor of Gastrointestinal Tract, Lung, and Thymus - Carcinoid TumorsNeuroendocrine Tumor of Gastrointestinal Tract, Lung, and Thymus - Carcinoid Tumors
Children with Severe Chronic Conditions on Medicaid | ASPEChildren with Severe Chronic Conditions on Medicaid | ASPE
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and Occupations
Thymus NeoplasmsThymus GlandThymus HyperplasiaPancreatic NeoplasmsNeoplasmsThymus PlantNeoplasms, Cystic, Mucinous, and SerousThymus ExtractsThymus HormonesSkin NeoplasmsThymectomyNeoplasms, Multiple PrimaryT-LymphocytesKidney NeoplasmsNeoplasms, Second PrimarySpleenThyroid NeoplasmsAdenocarcinoma, MucinousMyeloproliferative DisordersImmunohistochemistryDNA, NeoplasmLung NeoplasmsParotid NeoplasmsCystadenomaNeoplasms, ExperimentalNeoplasms, Connective and Soft TissueLiver NeoplasmsNeoplasms, Plasma CellAppendiceal NeoplasmsLymphomaCystadenoma, MucinousOvarian NeoplasmsEndocrine Gland NeoplasmsThymomaGastrointestinal NeoplasmsNeoplasms, Radiation-InducedCarcinoma, Pancreatic DuctalNeoplasms, Vascular TissueEye NeoplasmsNose NeoplasmsSalivary Gland NeoplasmsMice, Inbred C57BLAdenocarcinoma, PapillaryCarcinoma, PapillaryNeoplasm ProteinsLymphoid TissueTesticular NeoplasmsNeoplasms, Muscle TissueNeoplasms, Glandular and EpithelialThymocytesAntigens, NeoplasmAdenomaCystadenocarcinoma, MucinousSoft Tissue NeoplasmsHematologic NeoplasmsUterine NeoplasmsIntestinal NeoplasmsNeoplasms, Adnexal and Skin AppendageNeoplasm StagingVascular NeoplasmsCell DifferentiationSweat Gland NeoplasmsBone NeoplasmsPalatal NeoplasmsNeoplasms, Complex and MixedMandibular NeoplasmsCystadenocarcinomaMice, Inbred StrainsBile Duct NeoplasmsNeoplasm InvasivenessSplenic NeoplasmsDog DiseasesHeart NeoplasmsCystadenoma, SerousTumor Markers, BiologicalColonic NeoplasmsMaxillary NeoplasmsCattleT-Lymphocyte SubsetsAnal Gland NeoplasmsMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalBone Marrow NeoplasmsLymphocytesMice, TransgenicNeoplasms, Adipose TissueColorectal NeoplasmsMeningeal NeoplasmsLymph NodesDuodenal NeoplasmsMyasthenia GravisFlow CytometryAdrenal Cortex NeoplasmsMouth NeoplasmsReceptors, Antigen, T-CellTongue NeoplasmsMice, Inbred AKRAntigens, CD8Ileal NeoplasmsStomach NeoplasmsLiver Neoplasms, ExperimentalFetusImmunophenotypingUrinary Bladder NeoplasmsCarcinoma, Acinar CellCarcinomaSpinal Cord NeoplasmsVaginal NeoplasmsBone MarrowNeoplasm MetastasisAdenoma, OxyphilicNeoplasm Recurrence, LocalNervous System NeoplasmsAdenocarcinomaTomography, X-Ray ComputedMice, Inbred BALB CJanus Kinase 2Muscle NeoplasmsHemangiosarcomaDNAB-LymphocytesMyelodysplastic-Myeloproliferative DiseasesPancreatectomyLymphopoiesisPeripheral Nervous System NeoplasmsLipoma
Epithelial neoplasmsTumorsSurvivalPatientsThymomaGlandTumors of the thymusMyasthenia gravisCarcinomaLymph NodesPoorly differentiated neoplasmsLungPathologySpleenThyroidBenignNormal thymusCancerLymphoepithelial organCarcinomasCancersTracheaPrimaryTumor CellsLymphomaMediastinalReticulum cell neoplasmsEnlarges during chMediastinumHematopoieticOrganMedullaOrgansGastrointestinalGerm CellDifferentiationBone marrowThoracicParathyroidNeuroendocrine systemTissueLymphoidHeterogeneous group
Epithelial neoplasms1
Tumors1
Survival1
  • High EGFR immunoreactivity is seen in more aggressive thymic neoplasms as classified according to the 2004 WHO, but regardless of classification, the presence of EGFR in tumor cells (1+, 2+, and 3+) is associated with improved performance free survival (PFS) and a trend for better OS. (elsevier.com)
Patients1
  • A total of 456 patients who underwent surgery for thymic epithelial neoplasm at Mayo Clinic Rochester (1942 to 2008) were staged (modified Masaoka, proposed Moran, proposed IASLC/ITMIG) and independently classified by 3 thoracic pathologists (World Health Organization, proposed Suster & Moran [S&M], and Bernatz). (elsevier.com)
Thymoma22
Gland19
Tumors of the thymus7
Myasthenia gravis1
  • Fifteen patients had a thymus-related syndrome (in 13 patients it resulted myasthenia gravis ), and in 11 patients it improved or remitted after treatment of the pleural recurrence. (curehunter.com)
Carcinoma3
Lymph Nodes3
Poorly differentiated neoplasms3
Lung6
Pathology3
Spleen1
Thyroid5
Benign2
  • Most thymomas have the potential to behave like a cancer and spread beyond the thymus, but many appear to behave in a benign fashion and are noninvasive. (medicinenet.com)
  • The mediastinum is the site of onset of various types of cancers both of benign and malignant nature, among which thymus tumours and tumours originating from neural elements (neuromas) are the most frequent and treated by the thoracic surgeon . (ieo.it)
Normal thymus2
Cancer13
Lymphoepithelial organ1
Carcinomas4
Cancers3
Trachea1
  • Mediastinal tumors can be developped in the mediastinum - the area of the chest that separates the lungs and contains the heart, aorta, esophagus, thymus, and trachea. (ieo.it)
Primary2
Tumor Cells1
  • Thymus cell antigen 1 (Thy1), also known as cluster of differentiation (CD)90, is a 25-37-kDa glycophosphatidylinositol-anchored protein that is expressed in numerous cell types, including T cells, neurons, endothelial cells, fibroblasts and numerous tumor cells. (spandidos-publications.com)
Lymphoma5
Mediastinal2
Reticulum cell neoplasms2
  • Most of the tumours are pleomorphic or mixed-cell types commonly called type-B reticulum cell neoplasms by Dunn, but a few are type-A histiocytomas. (jax.org)
  • Ribonuclease activity in cell-free thymus homogenates was elevated for five strains of mice genetically predisposed toward leukemia or reticulum cell neoplasms (AKR, C58, PL, RF, and SJL). (rupress.org)
Enlarges during ch1
Mediastinum5
Hematopoietic4
  • Cells in the thymus can be divided into thymic stromal cells and cells of hematopoietic origin (derived from bone marrow resident hematopoietic stem cells). (wikipedia.org)
  • The thymus provides an inductive environment for development of T cells from hematopoietic progenitor cells. (wikipedia.org)
  • Niche functionality is likely affected not only by the genomic background of the myeloproliferative neoplasm-associated mutated hematopoietic stem cells, but also by disease-associated 'chronic inflammation', and subsequent adaptive and innate immune responses. (haematologica.org)
  • Philadelphia chromosome negative' myeloproliferative neoplasms (MPN) are a group of relatively rare hematologic diseases characterized by a clonal proliferation of blood cells, most commonly secondary to acquired hematopoietic stem cell (HSC) mutations that directly or indirectly induce upregulation of the JAK-STAT pathway. (haematologica.org)
Organ3
Medulla5
Organs1
Gastrointestinal1
Germ Cell1
Differentiation4
Bone marrow2
  • In this timely article, we will review current knowledge surrounding the deregulated bone marrow niche in myeloproliferative neoplasms and suggest how this may be targeted, either directly or indirectly, potentially influencing therapeutic choices both now and in the future. (haematologica.org)
  • Discover the latest research on Bone Marrow Neoplasms here. (meta.org)
Thoracic1
  • A total of 456 patients who underwent surgery for thymic epithelial neoplasm at Mayo Clinic Rochester (1942 to 2008) were staged (modified Masaoka, proposed Moran, proposed IASLC/ITMIG) and independently classified by 3 thoracic pathologists (World Health Organization, proposed Suster & Moran [S&M], and Bernatz). (elsevier.com)
Parathyroid1
Neuroendocrine system1
  • This review provides a comprehensive overview of the human neuroendocrine system and its neoplasms, from their discovery to current terminology and classifications. (prolekare.cz)
Tissue6
  • By the early teens, the thymus begins to atrophy and thymic stroma is mostly replaced by adipose (fat) tissue. (wikipedia.org)
  • The thymus of older people is scarcely distinguishable from surrounding fatty tissue. (wikipedia.org)
  • With aging the thymus slowly shrinks, eventually degenerating into tiny islands of fatty tissue. (wikipedia.org)
  • may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere. (icd10data.com)
  • During this descent, remnants of thymic tissue occasionally are implanted along the cervical pathway and may appear later as an ectopic cervical thymus (1) . (ajnr.org)
  • As a result, we scored the tissue microarrays (TMAs) for intensity of expression both at the junctional zone ("top"), as well as at the base ("bottom") of each melanocytic neoplasm in which the orientation of the lesion was clearly demonstrable in the specimen core present on the TMA section. (pnas.org)
Lymphoid1
Heterogeneous group1
Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on...
Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on... (mayoclinic.pure.elsevier.com)
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas |...
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas |... (clincancerres.aacrjournals.org)
Thymus Cancer | Thymoma | MedlinePlus
Thymus Cancer | Thymoma | MedlinePlus (medlineplus.gov)
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy - Full...
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy - Full... (clinicaltrials.gov)
Lymph Nodes, Spleen & Thymus
Lymph Nodes, Spleen & Thymus (webpathology.com)
Yellow Fever Vaccine
Yellow Fever Vaccine (cdc.gov)
Yellow Fever Symptoms, Vaccine, Treatment & History
Yellow Fever Symptoms, Vaccine, Treatment & History (medicinenet.com)
GTF2I Gene - GeneCards | GTF2I Protein | GTF2I Antibody
GTF2I Gene - GeneCards | GTF2I Protein | GTF2I Antibody (genecards.org)
Children with Severe Chronic Conditions on Medicaid | ASPE
Children with Severe Chronic Conditions on Medicaid | ASPE (aspe.hhs.gov)
Recruiting for Clinical Trials | New Mesothelioma Treatment Studies
Recruiting for Clinical Trials | New Mesothelioma Treatment Studies (mesothelioma.com)
Immunohistochemical studies in human thymomas. Localization of thymosin and various cell marker. | CureHunter
Immunohistochemical studies in human thymomas. Localization of thymosin and various cell marker. | CureHunter (curehunter.com)
ADR Common Drug -Induced Organ Disorders | Anemia | Drogas
ADR Common Drug -Induced Organ Disorders | Anemia | Drogas (pt.scribd.com)
Anmerkungen zur Geschichte der Thymusforschung | SpringerLink
Anmerkungen zur Geschichte der Thymusforschung | SpringerLink (link.springer.com)
Malignant mediastinal Germ Cell Tumors | health.am
Malignant mediastinal Germ Cell Tumors | health.am (health.am)
Pediatric Thymoma: Background, Pathophysiology, Epidemiology
Pediatric Thymoma: Background, Pathophysiology, Epidemiology (emedicine.medscape.com)
Anti-activated Notch1 antibody (ab8925) | Abcam
Anti-activated Notch1 antibody (ab8925) | Abcam (abcam.com)
Neuroendocrine Neoplasms | SpringerLink
Neuroendocrine Neoplasms | SpringerLink (link.springer.com)
Differential for an anterosuperior mediastinal mass | Radiology Reference Article | Radiopaedia.org
Differential for an anterosuperior mediastinal mass | Radiology Reference Article | Radiopaedia.org (radiopaedia.org)
The Age and Sex Distribution and Incidence of Neoplastic Diseases at the Memorial Hospital, New York City. | Annals of Internal...
The Age and Sex Distribution and Incidence of Neoplastic Diseases at the Memorial Hospital, New York City. | Annals of Internal... (annals.org)
Magnetic resonance imaging of the mediastinum, chest wall and pleura in children | SpringerLink
Magnetic resonance imaging of the mediastinum, chest wall and pleura in children | SpringerLink (link.springer.com)
Thyroid Gland | SpringerLink
Thyroid Gland | SpringerLink (link.springer.com)
Modern Journal of Animal Husbandry and Veterinary Medicine》-2018-04
Modern Journal of Animal Husbandry and Veterinary Medicine》-2018-04 (en.cnki.com.cn)
Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms | SpringerLink
Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms | SpringerLink (link.springer.com)
Human Metabolome Database: Showing Protein Neurogenic locus notch homolog protein 1 (HMDBP02331)
Human Metabolome Database: Showing Protein Neurogenic locus notch homolog protein 1 (HMDBP02331) (hmdb.ca)